Recommended principles and practices for validating clinical molecular pathology tests

Lawrence Jennings, Vivianna M. Van Deerlin, Margaret L. Gulley

Research output: Contribution to journalArticle

133 Citations (Scopus)

Abstract

The use of DNA- and RNA-based tests continues to grow for applications as varied as inherited disease, infectious disease, cancer, identity testing, human leukocyte antigen typing, and pharmacogenetics. Progress is driven in part by the huge growth in knowledge about the molecular basis of disease coupled with advancements in technologic capabilities. In addition to requirements for clinical utility, every molecular test also may have limitations that must be carefully considered before clinical implementation. Analytic and clinical performance characteristics as well as test limitations are established and documented through the process of test validation. Objective.-To describe the established principles of test validation, along with relevant regulations in the United States, in order to provide a rational approach to introducing molecular tests into the clinical laboratory. Data Sources.-PubMed review of published literature, published guidelines, and online information from national and international professional organizations. Conclusions.-These resources and recommendations provide a framework for validating clinical tests..

Original languageEnglish (US)
Pages (from-to)743-755
Number of pages13
JournalArchives of Pathology and Laboratory Medicine
Volume133
Issue number5
StatePublished - May 1 2009

Fingerprint

Clinical Pathology
Molecular Pathology
Information Storage and Retrieval
Pharmacogenetics
HLA Antigens
PubMed
Communicable Diseases
Guidelines
RNA
DNA
Growth
Neoplasms

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Cite this

@article{480d843007b640918452baf4f5c600b3,
title = "Recommended principles and practices for validating clinical molecular pathology tests",
abstract = "The use of DNA- and RNA-based tests continues to grow for applications as varied as inherited disease, infectious disease, cancer, identity testing, human leukocyte antigen typing, and pharmacogenetics. Progress is driven in part by the huge growth in knowledge about the molecular basis of disease coupled with advancements in technologic capabilities. In addition to requirements for clinical utility, every molecular test also may have limitations that must be carefully considered before clinical implementation. Analytic and clinical performance characteristics as well as test limitations are established and documented through the process of test validation. Objective.-To describe the established principles of test validation, along with relevant regulations in the United States, in order to provide a rational approach to introducing molecular tests into the clinical laboratory. Data Sources.-PubMed review of published literature, published guidelines, and online information from national and international professional organizations. Conclusions.-These resources and recommendations provide a framework for validating clinical tests..",
author = "Lawrence Jennings and {Van Deerlin}, {Vivianna M.} and Gulley, {Margaret L.}",
year = "2009",
month = "5",
day = "1",
language = "English (US)",
volume = "133",
pages = "743--755",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "5",

}

Recommended principles and practices for validating clinical molecular pathology tests. / Jennings, Lawrence; Van Deerlin, Vivianna M.; Gulley, Margaret L.

In: Archives of Pathology and Laboratory Medicine, Vol. 133, No. 5, 01.05.2009, p. 743-755.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Recommended principles and practices for validating clinical molecular pathology tests

AU - Jennings, Lawrence

AU - Van Deerlin, Vivianna M.

AU - Gulley, Margaret L.

PY - 2009/5/1

Y1 - 2009/5/1

N2 - The use of DNA- and RNA-based tests continues to grow for applications as varied as inherited disease, infectious disease, cancer, identity testing, human leukocyte antigen typing, and pharmacogenetics. Progress is driven in part by the huge growth in knowledge about the molecular basis of disease coupled with advancements in technologic capabilities. In addition to requirements for clinical utility, every molecular test also may have limitations that must be carefully considered before clinical implementation. Analytic and clinical performance characteristics as well as test limitations are established and documented through the process of test validation. Objective.-To describe the established principles of test validation, along with relevant regulations in the United States, in order to provide a rational approach to introducing molecular tests into the clinical laboratory. Data Sources.-PubMed review of published literature, published guidelines, and online information from national and international professional organizations. Conclusions.-These resources and recommendations provide a framework for validating clinical tests..

AB - The use of DNA- and RNA-based tests continues to grow for applications as varied as inherited disease, infectious disease, cancer, identity testing, human leukocyte antigen typing, and pharmacogenetics. Progress is driven in part by the huge growth in knowledge about the molecular basis of disease coupled with advancements in technologic capabilities. In addition to requirements for clinical utility, every molecular test also may have limitations that must be carefully considered before clinical implementation. Analytic and clinical performance characteristics as well as test limitations are established and documented through the process of test validation. Objective.-To describe the established principles of test validation, along with relevant regulations in the United States, in order to provide a rational approach to introducing molecular tests into the clinical laboratory. Data Sources.-PubMed review of published literature, published guidelines, and online information from national and international professional organizations. Conclusions.-These resources and recommendations provide a framework for validating clinical tests..

UR - http://www.scopus.com/inward/record.url?scp=65649113589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65649113589&partnerID=8YFLogxK

M3 - Article

C2 - 19415949

AN - SCOPUS:65649113589

VL - 133

SP - 743

EP - 755

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 5

ER -